• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

byStudy Graphics | C.WuandConstance Wu
September 6, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this case-control cohort study, treatment with glatiramer acetate, interferon-beta, fingolimod, alemtuzumab, and natalizumab all led to reduced conversion to secondary progressive multiple sclerosis (MS) compared to no Disease-Modifying Treatment (DMT).

2. Treatment with fingolimod, alemtuzumab, and natalizumab had reduced conversion to secondary progressive MS compared to glatiramer acetate and interferon-beta.

Evidence Rating Level: 2 (Good)

Study Rundown: Patients with relapsing-remitting MS generally convert to secondary progressive MS within a few decades of initial diagnosis. Though Disease Modifying Therapies (DMTs) are well-validated to treat MS symptoms and prevent exacerbations, it is unclear if they similarly reduce the conversion to secondary progressive MS. In this case-control cohort with prospectively collected clinical data, patients who received any DMT had reduced conversion to secondary progressive MS than those who did not. Further, those who received DMT closer to symptom appearance tended to have reduced conversion compared to those who started DMT later. The more potent DMTs studied (fingolimod, alemtuzumab, and natalizumab) had reduced conversion compared to glatiramer acetate and interferon-beta.

This study utilizes the newly set consensus definition for secondary progressive MS, and thus may be more accurate than similar studies completed previously. However, the study was limited by its cohort design and strict exclusion criteria that greatly reduced the proportion of patients eligible for study.

Click to read the study in JAMA

Image: PD

RELATED REPORTS

Palliative care improves satisfaction in patients with progressive neurologic diseases and their caregivers

Serum glial fibrillary acidic protein may be a useful prognostic marker of disease progression in multiple sclerosis

The 2 Minute Medicine Podcast Episode 1

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: disease-modifying treatment (DMT)multiple sclerosis
Previous Post

Quick Take: Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

Next Post

Quick Take: Neutrophil–Lymphocyte Ratio as a Predictor of Kidney Function Decline Among Diabetes and Pre-diabetes (a 3-year follow-up study)

RelatedReports

Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine
Chronic Disease

Palliative care improves satisfaction in patients with progressive neurologic diseases and their caregivers

March 28, 2023
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Serum glial fibrillary acidic protein may be a useful prognostic marker of disease progression in multiple sclerosis

February 12, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 1

February 9, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Last Dance, Head of State, Trouble on the Farm and the Heart of COVID-19!

November 1, 2022
Next Post
Solitary kidney not associated with contrast-induced nephropathy

Quick Take: Neutrophil–Lymphocyte Ratio as a Predictor of Kidney Function Decline Among Diabetes and Pre-diabetes (a 3-year follow-up study)

Computed tomography improves diagnostic certainty in the emergency department

Rising handgun ownership linked to increased firearm mortalities among young children

Children’s hospital visits for suicide ideation and attempts are increasing

Quick Take: Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options